این سایت در حال حاضر پشتیبانی نمی شود و امکان دارد داده های نشریات بروز نباشند
International Journal of Hematology-Oncology and Stem Cell Research، جلد ۱۰، شماره ۲، صفحات ۷۰-۷۸
عنوان فارسی
چکیده فارسی مقاله
کلیدواژه‌های فارسی مقاله
عنوان انگلیسی JAK2V617F Allele Burden Measurement in Peripheral Blood of Iranian Patients with Myeloproliferative Neoplasms and Effect of Hydroxyurea on JAK2V617F Allele Burden
چکیده انگلیسی مقاله Background: Myeloproliferative neoplasms (MPNs) are clonal malignant diseases that represent a group of conditions including polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis (PMF). The aim of this study was to evaluate possible correlations between JAK2V617F allele burden and clinicohematologic characteristics in Iranian patients with MPNs. We also aimed at determining the correlation between JAK2V617F allele burden and use of cytoreductive treatment (hydroxyurea). Materials and Methods: We performed ARMS-PCR for all MPNs samples and subsequently performed real-time quantitative polymerase chain reaction (qRT-PCR) for JAK2V617F allele burden measurement using DNA from peripheral blood leukocytes. Results: Two distinct groups of patients were examined at a single time point: group A (n=40; 20 PV, 20 ET) was examined at the time of diagnosis; group B (n=85; 40 PV, 30 ET and 15 PMF) while under treatment with hydroxyurea (HU). The median allele burden of the JAK2 V617F was 72% for PV and 49% for ET patients at the time of diagnosis (p=0.01). For patients with HU treatment, we determined the median JAK2V617F allele burden to be 43%, 40%, and 46.5 % in PV, ET and PMF patients; respectively. HU-treated PV patients had a significant lower %JAK2V617F than PV patients at the time of diagnosis (43% vs. 72%, p=0.005). In ET group, the relationship between the JAK2 V617F allele burden and leukocyte count was significant (p=0.02 and p=0.01 in untreated and treated patients, respectively). Conclusions: Our results showed that patients with PV have a higher JAK2V617F allele burden. Moreover, our study demonstrated that the JAK2V617F allele burden correlates with clinical features in ET group. We also showed hydroxyurea can affect the JAK2V617F allele burden in PV patients.
کلیدواژه‌های انگلیسی مقاله Hydroxyurea,JAK2V617F,Myeloproliferative neoplasms
نویسندگان مقاله شیرین فردوسی | shirin ferdowsi
blood transfusion research center, high institute for research and education in transfusion medicine, tehran, iran

سازمان اصلی تایید شده: سازمان انتقال خون ایران (Blood transfusion research center)

سید h غفاری | seyed h ghaffari
hematology- oncology and stem cell transplantation research center, tehran university of medical sciences, tehran, iran

سازمان اصلی تایید شده: دانشگاه علوم پزشکی تهران (Tehran university of medical sciences)

ناصر امیری زاده | naser amirizadeh
blood transfusion research center, high institute for research and education in transfusion medicine, tehran, iran

سازمان اصلی تایید شده: سازمان انتقال خون ایران (Blood transfusion research center)

آزیتا آذرکیوان | azita azarkeivan
blood transfusion research center, high institute for research and education in transfusion medicine, tehran, iran

سازمان اصلی تایید شده: سازمان انتقال خون ایران (Blood transfusion research center)

کامران عطاردی | kamran atarodi
blood transfusion research center, high institute for research and education in transfusion medicine, tehran, iran

سازمان اصلی تایید شده: سازمان انتقال خون ایران (Blood transfusion research center)

محمد فرانوش | mohammad faranoush
blood transfusion research center, high institute for research and education in transfusion medicine, tehran, iran

سازمان اصلی تایید شده: سازمان انتقال خون ایران (Blood transfusion research center)

غلامرضا توگه | gholamreza toogeh
hematology-oncology and bmt research center, imam khomeini hospital, tehran university of medical sciences, tehran, iran

سازمان اصلی تایید شده: دانشگاه علوم پزشکی تهران (Tehran university of medical sciences)

رضا شیرکوهی | reza shirkoohi
molecular genetics, cancer research center, cancer institute, imam khomeini hospital complex, tehran university of medical sciences, tehran, iran

سازمان اصلی تایید شده: دانشگاه علوم پزشکی تهران (Tehran university of medical sciences)

محمد واعظی | mohammad vaezi
hematology- oncology and stem cell transplantation research center, tehran university of medical sciences, tehran, iran

سازمان اصلی تایید شده: دانشگاه علوم پزشکی تهران (Tehran university of medical sciences)

مهتاب مقصودلو | mahtab maghsoodlu
blood transfusion research center, high institute for research and education in transfusion medicine, tehran, iran

سازمان اصلی تایید شده: سازمان انتقال خون ایران (Blood transfusion research center)

کامران علی مقدم | kamran alimoghaddam
hematology- oncology and stem cell transplantation research center, tehran university of medical sciences, tehran, iran

سازمان اصلی تایید شده: دانشگاه علوم پزشکی تهران (Tehran university of medical sciences)

اردشیر قوام زاده | ardeshir ghavamzadeh
hematology- oncology and stem cell transplantation research center, tehran university of medical sciences, tehran, iran

سازمان اصلی تایید شده: دانشگاه علوم پزشکی تهران (Tehran university of medical sciences)

حسین تیموری نقده | hosein teimori naghadeh
blood transfusion research center, high institute for research and education in transfusion medicine, tehran, iran

سازمان اصلی تایید شده: سازمان انتقال خون ایران (Blood transfusion research center)

نشانی اینترنتی http://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/346
فایل مقاله فایلی برای مقاله ذخیره نشده است
کد مقاله (doi)
زبان مقاله منتشر شده en
موضوعات مقاله منتشر شده
نوع مقاله منتشر شده Articles
برگشت به: صفحه اول پایگاه   |   نسخه مرتبط   |   نشریه مرتبط   |   فهرست نشریات